Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2011-07-19
2011-07-19
Bowman, Amy (Department: 1635)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C435S320100, C536S023100, C536S024500
Reexamination Certificate
active
07981870
ABSTRACT:
RNA interference is provided for inhibition of HIF1A mRNA expression for treating patients with ocular angiogenesis, particularly for treating retinal edema, diabetic retinopathy, sequela associated with retinal ischemia, posterior segment neovascularization (PSNV), and neovascular glaucoma, and for treating patients at risk of developing such conditions.
REFERENCES:
patent: 7217572 (2007-05-01), Ward et al.
patent: 2004/0101858 (2004-05-01), Ward et al.
patent: 2004/0220393 (2004-11-01), Ward et al.
patent: 2005/0255487 (2005-11-01), Khvorova et al.
patent: 03085110 (2003-10-01), None
patent: 2004042024 (2004-05-01), None
patent: 2005032486 (2005-04-01), None
patent: 2005035759 (2005-04-01), None
patent: 2005116204 (2005-08-01), None
patent: 2007002718 (2007-01-01), None
Canadian patent application No. 2,566,286 Abstract only; Corresponds to WO2005116204 dated Aug. 12, 2005; RNAi Co., Ltd.
Beppu, K., et al.; “Topotecan blocks hypoxia-inducible factor-1alpha and vascular endothelial growth factor expression induced by insulin-like growth factor-I in neuroblastoma cells”; Cancer Res.; 65:4775-4781; 2005.
Freeman, R.S., et al.; “Targeting hypoxia-inducible factor (HIF) as a therapeutic strategy for CNS disorders”; Curr Drug Targets CNS Neurol Disord. 4:85-92; 2005.
Kim, B., et al.; “Inhibition of ocular angiogenesis by siRNA targeting vascular endothelial growth factor pathway genes: therapeutic strategy for herpetic stromal keratitis”; Am J Pathol. 165:2177-2185; 2004.
Li, L., et al.; “Evaluating hypoxia-inducible factor-1alpha as a cancer therapeutic target via inducible RNA interference in vivo”; Cancer Res.; 65:7249-7258; 2005.
Mahato, et al.; “Modulation of gene expression by antisense and antigene oligodeoxynucleotides and small interfering RNA”; Expert Opin. Drug Deily.; vol. 2; No. 1; pp. 3-28; 2005.
Reich, S.J., et al.; “Small interfering RNA (siRNA) targeting VEGF effectively inhibits ocular neovascularization in a mouse model”; Mol Vis.; 9:210-216; 2003.
Ricker, J.L., et al.; “2-methoxyestradiol inhibits hypoxia-inducible factor 1alpha, tumor growth, and angiogenesis and augments paclitaxel efficacy in head and neck squamous cell carcinoma”; Clin Cancer Res. 10:8665-8673; 2004.
Scherer and Rossi; “Approaches for the sequence-specific knockdown of mRNA”; Nature Biotechnology; vol. 21; No. 12; pp. 1457-1465; Dec. 2003.
Shen, J. et al.; “Suppression of ocular neovascularization with siRNA targeting VEGF receptor 1”; Gene Ther.; 13:225-234; 2006.
Tolentino, M.J., et al; “Intravitreal injection of vascular endothelial growth factor small interfering RNA inhibits growth and leakage in a nonhuman primate, laser-induced model of choroidal neovascularization”; Retina; 24:132-138; 2004.
Wang, et al.; “Inhibition of Retinal Neovascularization by Intravitreous Delivery of HIF1a.siRNA in a Mice Model of Oxygen Induced Retinopathy”; IVOS; vol. 46, No. Suppl. S, 2005, p. 5202.
Zhang, X., et al.; “Enhancement of hypoxia-induced tumor cell death in vitro and radiation therapy in vivo by use of small interfering RNA targeted to hypoxia-inducible factor-1alpha”; Cancer Res. 64:8139-8142; 2004.
Zhang and Hua; “Targeted gene silencing by small interfering RNA-based knock-down technology”; Current Pharmaceutical Biotechnology; vol. 5; pp. 1-7; 2004.
Kim, D.H., et al.; “Synthetic dsRNA dicer substrates enhance RNAi potency and efficacy”; Nature Biotechnology; 23:2;222-226.
Bingaman David P.
Chatterton Jon E.
Alcon Research, Ltd.
Bowman Amy
Derry Jason J.
LandOfFree
RNAi-mediated inhibition of H1F1A for treatment of ocular... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with RNAi-mediated inhibition of H1F1A for treatment of ocular..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and RNAi-mediated inhibition of H1F1A for treatment of ocular... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2701722